NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...

While inducing GLP-1, the drug also reduces GIP activity ... It aims to do this, according to Reuters, by preventing the activity of a protein called myostatin, which negatively regulates skeletal ...

China’s Harbour BioMed has launched a new biotech to develop bispecific antibodies focused on the holy grail of next-gen ...

Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

It is expected to be completed next year. Scholar Rock The drug developer is testing apitegromab, an experimental therapy that targets the myostatin protein, alongside GLP-1 treatments. Its drug ...

EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...